Clinical Trial

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 1, 2019 (before its estimated November 1, 2021 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-01-24; most recent amendment 2019-01-31.
Trial Details
NCT Number NCT03818334
Lead Sponsor Hospital Israelita Albert Einstein
Conditions Bone Marrow Transplant Complications, Graft Versus Host Disease, Infection Viral, Engraft Failure, Immunologic Suppression
Enrollment 50 participants
Start Date 2018-11-06
Primary Completion 2021-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2019-02-01